Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AveXis, Inc.

http://avexis.com/

Latest From AveXis, Inc.

Zolgensma First To Be Subject To New German Data Collection Rules

The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.

Commercial Health Technology Assessment

Novartis Shows Importance Of Gene Therapy With AveXis Name Change

Novartis has completed its absorption of AveXis and rebranded the acquired gene therapy specialist that developed the soon-to-be SMA blockbuster Zolgensma despite struggling to meet the data integrity standards of regulators and big pharma.

Gene Therapy Companies

Roctavian’s Durability: For The Price, Payers Wanted Longer-Term Proof Anyway

FDA’s decision to seek two more years of data for BioMarin’s gene therapy for hemophilia A ‘makes perfect sense,’ Harvard Pilgrim Health Care’s Michael Sherman says.

Reimbursement Gene Therapy

Zolgensma First To Be Subject To New German Data Collection Rules

The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.

Gene Therapy Real-World Evidence
See All

Company Information

  • Other Names / Subsidiaries
    • BioLife Cell Bank, Inc.
UsernamePublicRestriction

Register